Loading clinical trials...
Loading clinical trials...
The Wearing-off Effect of Anti-CD20 Therapies in Patients With Multiple Sclerosis
Conditions
Interventions
ocrelizumab
ofatumumab
Locations
1
United States
Novartis Investigative Site
East Hanover, New Jersey, United States
Start Date
December 4, 2023
Primary Completion Date
June 13, 2025
Completion Date
June 13, 2025
Last Updated
July 11, 2025
NCT07325292
NCT05748015
NCT06433765
NCT04876339
NCT07466823
NCT05344469
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions